Drug Trial Radar · NCT05755048
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
314
Planned (sponsor's estimate)
Start
Mar 28, 2023
Primary completion
Jul 30, 2025
Study completion Jan 31, 2026
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of FS-1502 versus T-DM1 in HER2-positive, unresectable locally advanced or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Conditions
- Breast Cancer
Interventions
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)Biological
Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)Biological
Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Based on Independent Central Review (ICR) in Participants With HER2-Positive, Unresectable locally advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane.Time frame: Up to 28 months.
Locations
56 sites in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital of bengbu medical college
Bengbu, Anhui, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Chinese People's Liberation Army General Hospital fifth Medical Center South ward
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Recruiting
Chinese People's Liberation Army Army Special Medical Center
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Fuzhou, Fujian, China · Recruiting
The first affiliated hospital of xiamen university
Xiamen, Fujian, China · Recruiting
The first Hospital of lanzhou University
Lanzhou, Gansu, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Shantou University School of Medicine Affiliated Cancer Hospital
Shantou, Guangdong, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
Shenzhen, Guangdong, China · Recruiting
Guangxi Medical Univesity Cancer Hospital
Nanning, Guangxi, China · Recruiting
The First Afeliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
AnYang Cancer Hospital
Anyang, Henan, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Renmin Hospital Of Wuhan University
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
The Second Xiangya Hospital, Central South University
Changsha, Hunan, China · Recruiting
Chenzhou No.1 People's Hospital
Chenzhou, Hunan, China · Recruiting
The Central Hospital of Yongzhou
Yongzhou, Hunan, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Nanchang People's Hospital
Nanchang, Jiangxi, China · Recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
Liaoning cancer hospital & institute
Shenyang, Liaoning, China · Not yet recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.